AU526202B2 - Buspirone anti-anxiety method - Google Patents

Buspirone anti-anxiety method

Info

Publication number
AU526202B2
AU526202B2 AU47295/79A AU4729579A AU526202B2 AU 526202 B2 AU526202 B2 AU 526202B2 AU 47295/79 A AU47295/79 A AU 47295/79A AU 4729579 A AU4729579 A AU 4729579A AU 526202 B2 AU526202 B2 AU 526202B2
Authority
AU
Australia
Prior art keywords
buspirone
anxiety
anxiety method
buspirone anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU47295/79A
Other languages
English (en)
Other versions
AU4729579A (en
Inventor
George P. Casten
Gordon R. Mckinney
Roger E. Newton
E. Crosby Tompkins
John H. Weikel Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25426020&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU526202(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of AU4729579A publication Critical patent/AU4729579A/en
Application granted granted Critical
Publication of AU526202B2 publication Critical patent/AU526202B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU47295/79A 1978-05-22 1979-05-22 Buspirone anti-anxiety method Expired AU526202B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US05/908,597 US4182763A (en) 1978-05-22 1978-05-22 Buspirone anti-anxiety method
US908597 1978-05-22

Publications (2)

Publication Number Publication Date
AU4729579A AU4729579A (en) 1979-11-29
AU526202B2 true AU526202B2 (en) 1982-12-23

Family

ID=25426020

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47295/79A Expired AU526202B2 (en) 1978-05-22 1979-05-22 Buspirone anti-anxiety method

Country Status (7)

Country Link
US (1) US4182763A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS54163587A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU526202B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE876455A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE2920739A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH14486A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA792456B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4305944A (en) * 1980-09-08 1981-12-15 Mead Johnson & Company N-[(4-[3-cyano substituted pyridyl]piperazino)alkyl]-azaspirodecanediones
US4367335A (en) * 1981-08-03 1983-01-04 Mead Johnson & Company Thiazolidinylalkylene piperazine derivatives
US4411901A (en) * 1981-12-23 1983-10-25 Mead Johnson & Company Benzisothiazole and benzisoxazole piperazine derivatives
US4507303A (en) * 1981-12-22 1985-03-26 Sumitomo Chemical Company, Limited Succinimide derivatives, compositions and method of use
US4452799A (en) * 1981-12-23 1984-06-05 Mead Johnson & Company Benzisothiazole and benzisoxazole piperazine derivatives
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4361565A (en) * 1981-12-28 1982-11-30 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyridines
JPS5976059A (ja) * 1982-10-21 1984-04-28 Sumitomo Chem Co Ltd 環状イミド誘導体及びその酸付加塩
US4438119A (en) 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
US4581357A (en) * 1983-02-07 1986-04-08 Mead Johnson & Company Antipsychotic 5-fluoro-pyrimidin-2-yl piperazine compound
FR2540499B1 (fr) * 1983-02-07 1986-09-26 Bristol Myers Co Derive de 5-fluoro-pyrimidine-2-yl piperazine antipsychotique
US4612312A (en) * 1984-07-30 1986-09-16 Merrell Dow Pharmaceuticals Inc. Glutarimide antianxiety and antihypertensive agents
JPH0625181B2 (ja) * 1985-03-27 1994-04-06 住友製薬株式会社 新規なイミド誘導体
HUT43600A (en) * 1985-06-22 1987-11-30 Sandoz Ag Process for production of new thiazole derivatives and medical compound containing those
US4634703A (en) * 1985-10-25 1987-01-06 Bristol-Myers Company Method for alleviation of panic disorders
US4640921A (en) * 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
AR242678A1 (es) * 1986-03-05 1993-04-30 Gonzalez Jorge Alberto Mejoras en instrumentos musicales de cuerda de arco.
US4687772A (en) * 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
DD263531A5 (de) * 1986-10-21 1989-01-04 ������@���Kk�� Verfahren zur herstellung von verbrueckten bicyclischen imidverbindungen
US4777173A (en) * 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
SE8704097D0 (sv) * 1987-10-22 1987-10-22 Astra Ab Oral formulation of buspirone and salts thereof
DE3736974A1 (de) * 1987-10-31 1989-05-11 Troponwerke Gmbh & Co Kg Verwendung von 2-pyrimidinyl-1-piperazin-derivaten
US5242911A (en) * 1988-06-17 1993-09-07 Pfizer Inc. Bridged bicyclic imides as anxiolytics and antidepressants
US5468749A (en) * 1988-08-30 1995-11-21 Gawin; Frank H. Method for treatment of substance addiction
US5185329A (en) * 1988-08-30 1993-02-09 Bristol-Myers Squibb Company Method for treatment of substance addiction
WO1990008148A1 (en) * 1989-01-23 1990-07-26 Pfizer Inc. Bis-aza-bicyclic anxiolytic agents
US5162321A (en) * 1989-12-20 1992-11-10 Adir Et Compagnie 1-naphthyl piperazines useful as 5-HT1A receptor ligands
US6432956B1 (en) 1990-02-12 2002-08-13 William C. Dement Method for treatment of sleep apneas
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
US5342951A (en) * 1992-04-01 1994-08-30 G.D. Searle & Co. 2- and 3-sulfur derivatives of 1,5-iminosugars
US5268482A (en) * 1992-04-01 1993-12-07 G. D. Searle & Co. 2- and 3-sulfur derivatives of 1,5-iminosugars
US5331096A (en) * 1992-04-01 1994-07-19 G. D. Searle & Co. 2- and 3-sulfur derivatives of 1,5-iminosugars
US5206251A (en) * 1992-04-01 1993-04-27 G. D. Searle & Co. 2- and 3- amino and azido derivatives of 1,5-iminosugars
US5258518A (en) * 1992-04-01 1993-11-02 G. D. Searle & Co. 2-substituted tertiary carbinol derivatives of deoxynojirimycin
US5216168A (en) * 1992-04-01 1993-06-01 G. D. Searle & Co. 2- and 3- amino and azido derivatives of 1,5-iminosugars
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
EP0783503B1 (en) * 1994-09-30 2001-11-28 Pfizer Inc. 2,7-substituted octahydro-1h-pyrido[ 1,2-a]pyrazine derivatives
US5602128A (en) * 1994-12-02 1997-02-11 American Home Products Corporation N-heterocycloalkyl carboxamides as serotonergic agents
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
FR2795645B1 (fr) 1999-06-30 2001-09-21 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
US6566361B2 (en) 1999-06-30 2003-05-20 Laboratories, Upsa Azapirone pain treatment
US6218395B1 (en) * 1999-08-02 2001-04-17 Conrad Melton Swartz Centrally-acting beta-blockers and serotonin-enhancers for the treatment of anxiety disorders and adjustment disorders with anxiety
US20050137206A1 (en) * 1999-08-05 2005-06-23 Yevich Joseph P. Method for treatment of anxiety and depression
US6150365A (en) * 1999-08-05 2000-11-21 Bristol-Myers Squibb Company Anxiety method
US20030069251A1 (en) * 1999-08-05 2003-04-10 Yevich Joseph P. Antianxiety composition
EP2896624B1 (en) 2007-03-28 2016-07-13 Atir Holding S.A. Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof
JP5358571B2 (ja) 2007-08-07 2013-12-04 プロサリク リミテッド セロトニン作動性調節因子としての１，２，４−トリアゾール誘導体
EP2627328B1 (en) 2010-10-15 2016-09-14 Contera Pharma APS Combinations of serotonin receptor agonists for treatment of movement disorders
ES2654787T3 (es) 2012-04-18 2018-02-15 Contera Pharma Aps Formulación farmacéutica disponible por vía oral adecuada para la gestión mejorada de trastornos del movimiento
WO2018011181A1 (en) 2016-07-11 2018-01-18 Contera Pharma Aps Pulsatile drug delivery system for treating morning akinesia
RU2660583C1 (ru) * 2017-08-15 2018-07-06 Общество С Ограниченной Ответственностью "Валента - Интеллект" Применение буспирона для лечения функционального головокружения

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones

Also Published As

Publication number Publication date
JPS54163587A (en) 1979-12-26
AU4729579A (en) 1979-11-29
BE876455A (fr) 1979-11-22
ZA792456B (en) 1980-06-25
US4182763A (en) 1980-01-08
DE2920739A1 (de) 1979-12-06
PH14486A (en) 1981-08-07
DE2920739C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-08-08
JPS611008B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1986-01-13

Similar Documents

Publication Publication Date Title
AU526202B2 (en) Buspirone anti-anxiety method
AU519317B2 (en) 6-substituted thia-aza compounds
AU531757B2 (en) Pyrimidones
AU4620679A (en) An improved process
AU519893B2 (en) Weatherstrip
AU523471B2 (en) Defrosting method
AU518041B2 (en) 3-azolyl-benzotriazines and -benzotriazine 1-oxides
AU5165479A (en) Substituted 1-thia-3-aza-4-ones
AU531439B2 (en) Cooling coke
AU5147579A (en) Weatherstrip
AU519357B2 (en) Substituted 2-phenylimino-imidazolidines
AU5399879A (en) Substituted trifluoroethylamines
AU4678379A (en) Substituted aklanyl-azolyl oxime-carbamates
AU523176B2 (en) Oxyhydrochlorination process
AU4369979A (en) Substituted n-acyl-amino-tetrahydro-2-furanones
AU523867B2 (en) Substituted n-iminomethylpiperidines
AU532933B2 (en) Multipackaging method
AU527112B2 (en) Cooling method
AU4879379A (en) Substituted 2-phenylamino-2-imidazolines
SU688622A1 (ru) Способ разработки грунтов
AU513987B2 (en) (1-alkyl-5-nitro-2-imidazolyl)-vinyl-glyoxal-diacetals
AU507933B2 (en) Substituted n-cyclohexyl-isothioureas
AU510875B2 (en) l-acyl-4 (0-halophenyl)-3-thiosemicarbazides
AU522479B2 (en) Sealing method
AU4374179A (en) Carbonate process